6 Jun 2017 11:05
Realm Therapeutics plc
("Realm Therapeutics" or the "Company")
Result of 2017 Annual General Meeting
6 June 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, today announces that all Resolutions put to shareholders were duly passed at its Annual General Meeting held earlier today. Proxy figures will be displayed shortly on the Company's website at www.realmtx.com.
Enquiries:
Realm Therapeutics plc | +44 (0) 20 3727 1000 | |
Alex Martin, Chief Executive Officer Marella Thorell, Chief Financial Officer and Chief Operating Officer | ||
FTI Consulting | +44 (0) 20 3727 1000 | |
Simon Conway / Mo Noonan | ||
N+1 Singer (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 | |
Aubrey Powell / Lauren Kettle | ||
About Realm Therapeutics
Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programmes, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.
RLM.L (RLM)